

Appln. No. 09/537,859
Amdt. dated December 23, 2004
Reply to Office action of July 23, 2004

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-23 (Cancelled).

24 (Currently Amended). An isolated amino-terminally truncated MCP-2 polypeptide consisting of comprising-residues 2-76 of an MCP-2 polypeptide according to SEQ ID NO:2, wherein the truncated MCP-2 polypeptide lacks NH₂-terminal amino acid residue 1 of SEQ ID NO:2 and has chemokine antagonistic activity.

25 (Currently Amended). An isolated amino-terminally truncated MCP-2 polypeptide consisting of comprising-residues 3-76 of an MCP-2 polypeptide according to SEQ ID NO:2, wherein the truncated MCP-2 polypeptide lacks NH₂-terminal amino acid residues 1-2 of SEQ ID NO:2 and has chemokine antagonistic activity.

26 (Currently Amended). An isolated amino-terminally truncated MCP-2 polypeptide consisting of comprising-residues 4-76 of an MCP-2 polypeptide according to MCP-2 (SEQ ID NO: 2), wherein the truncated MCP-2 polypeptide lacks NH₂-terminal amino acid residues 1-3 of SEQ ID NO:2 and has chemokine antagonistic activity.